Beckton Dickinson Gets Clearance for CPO Detection Test
BD’s Phoenix carbapenemase-producing organism (CPO) phenotypic detection test received marketing clearance from the FDA.
The device is the latest addition to BD’s diagnostics product line, which includes the BD Phoenix M50, an automated microbiology system used to test susceptibility.
The phenotypic detection test is used to identify CPO-caused infections. It can deliver results in less than 36 hours and may be faster than conventional phenotypic methods.